Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19483367 | 0.83 | ECE1 (0.30) | ECE1 | |
| SCHEMBL19483386 | 0.83 | ECE1 (0.30) | ECE1 | |
| SCHEMBL14519715 | 0.81 | CA2 (0.42) | CA2CA1MAPK1SLC1A3SLC1A2 | |
| SCHEMBL15658499 | 0.80 | ALDH1A1 (0.39) | CA2CA1MAPK1SLC1A3SLC1A2 | |
| SCHEMBL3833965 | 0.77 | CA2 (0.54) | CA2CA1MAPK1SLC1A3SLC1A2 | |
| SCHEMBL10034713 | 0.76 | ECE1 (0.34) | CA2CA1ECE1 | |
| SCHEMBL1705139 | 0.76 | ECE1 (0.34) | CA2CA1ECE1 | |
| SCHEMBL4756185 | 0.75 | SLC1A3 (0.52) | CA2CA1MAPK1SLC1A3SLC1A2 | |
| SCHEMBL4756180 | 0.75 | SLC1A3 (0.52) | CA2CA1MAPK1SLC1A3SLC1A2 | |
| SCHEMBL16683908 | 0.75 | SLC1A3 (0.52) | CA2CA1MAPK1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | CA2 4015/4885CA1 3499/4885MAPK1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.